ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab.
Stefanini B, Fulgenzi CAM, Scheiner B, Korolewicz J, Cheon J, Nishida N, Ang C, Marron TU, Wu YL, Saeed A, Wietharn B, Rimassa L, Pirozzi A, Cammarota A, Pressiani T, Pinter M, Balcar L, Huang YH, Mehan A, Phen S, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Samson A, Galle PR, Kudo M, Manfredi GF, Celsa C, Awosika N, Cortellini A, Singal AG, Sharma R, Chon HJ, Tovoli F, Piscaglia F, Pinato DJ, D'Alessio A.
Stefanini B, et al. Among authors: d alessio a.
J Hepatocell Carcinoma. 2025 Apr 4;12:671-683. doi: 10.2147/JHC.S462701. eCollection 2025.
J Hepatocell Carcinoma. 2025.
PMID: 40201222
Free PMC article.